SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation.

In stage III, unresectable PD-L1–positive NSCLC after platinum-based concurrent chemoradiation, tiragolumab plus atezolizumab did not improve IRF-assessed PFS (19.4 vs 16.6 months).

• Why it matters: The study addressed whether adding tiragolumab to atezolizumab could improve outcomes beyond durvalumab consolidation after chemoradiation in this setting.
• What they did: In SKYSCRAPER-03 (NCT04513925), patients were randomized 1:1 to tiragolumab 840 mg Q4W plus atezolizumab 1680 mg Q4W versus durvalumab, with primary analysis of IRF-assessed PFS in PD-L1–positive tumors (≥1%).
• The result: After 33.0 months median follow-up, the stratified hazard ratio for PFS was 0.96 (95% CI 0.75–1.23, P=0.76) and the primary endpoint was not met; safety showed no new unexpected findings.

AI summary of the abstract · may contain errors · not medical advice · read the paper.